Technical Analysis for ACRX - AcelRx Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade C 3.16 -2.77% -0.09
ACRX closed down 2.77 percent on Friday, March 22, 2019, on 73 percent of normal volume. The stock fell below its 200 day moving average, damaging its long-term outlook by crossing under that critical trendline.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Flat
See historical ACRX trend table...

Date Alert Name Type % Chg
Mar 22 Fell Below 200 DMA Bearish 0.00%
Mar 22 Wide Bands Range Expansion 0.00%
Mar 22 Down 3 Days in a Row Weakness 0.00%
Mar 21 Fell Below 20 DMA Bearish -2.77%
Mar 21 200 DMA Support Bullish -2.77%
Mar 21 Wide Bands Range Expansion -2.77%
Mar 20 20 DMA Support Bullish -5.67%
Mar 20 Wide Bands Range Expansion -5.67%
Mar 19 Crossed Above 200 DMA Bullish -7.33%
Mar 19 Crossed Above 20 DMA Bullish -7.33%

Older signals for ACRX ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
AcelRx Pharmaceuticals, Inc., a development stage specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute and breakthrough pain. The company's principal product candidate is ARX-01, a Sufentanil NanoTab PCA system, which is in Phase III clinical trials for acute post-operative pain in patients in the hospital setting. Its product candidates also comprise ARX-02, a Sufentanil NanoTab BTP management system that has completed a Phase II clinical trial for the treatment of cancer patients who suffer from breakthrough pain; and ARX-03, a Sufentanil/Triazolam NanoTab, which has completed a Phase II clinical trial to provide mild sedation, anxiety reduction, and pain relief for patients undergoing painful procedures in a physician's office. In addition, the company's product candidate under development includes ARX-04, a Sufentanil Single-Dose NanoTab for the treatment of patients with moderate-to-severe acute pain either on the battlefield or in civilian settings of trauma or injury. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Redwood City, California.
Chemistry Cancer Pain Chemical Compounds Organic Compounds Treatment Of Cancer Clinical Trial Injury Ethers Piperidines Fentanyl Stage Specialty Pharmaceutical Breakthrough Pain Sufentanil Thiophenes
Is ACRX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 5.05
52 Week Low 1.99
Average Volume 2,422,102
200-Day Moving Average 3.2205
50-Day Moving Average 2.9034
20-Day Moving Average 3.327
10-Day Moving Average 3.163
Average True Range 0.2669
ADX 16.28
+DI 22.2267
-DI 20.8133
Chandelier Exit (Long, 3 ATRs ) 3.2893
Chandelier Exit (Short, 3 ATRs ) 3.6907
Upper Bollinger Band 3.8386
Lower Bollinger Band 2.8154
Percent B (%b) 0.34
BandWidth 30.754433
MACD Line 0.0665
MACD Signal Line 0.1047
MACD Histogram -0.0382
Fundamentals Value
Market Cap 143.4 Million
Num Shares 45.4 Million
EPS -1.10
Price-to-Earnings (P/E) Ratio -2.87
Price-to-Sales 5.25
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.41
Resistance 3 (R3) 3.43 3.36 3.37
Resistance 2 (R2) 3.36 3.29 3.35 3.36
Resistance 1 (R1) 3.26 3.25 3.22 3.24 3.34
Pivot Point 3.19 3.19 3.17 3.18 3.19
Support 1 (S1) 3.09 3.13 3.06 3.08 2.98
Support 2 (S2) 3.02 3.09 3.01 2.96
Support 3 (S3) 2.92 3.02 2.95
Support 4 (S4) 2.91